Author Affiliations: Division of Infectious Diseases, Department of Internal Medicine (Drs Beerepoot and Geerlings), Department of General Practice (Dr ter Riet), Academic Medical Center, Amsterdam, the Netherlands.
We thank Dr Faasse for his thoughtful comments. We agree that it would have been clearer to use the term “inconclusive” instead of the one we used.
As far as we are aware, there are no validated rules to determine noninferiority margins. Nor can there be, since almost every clinical situation has its own peculiarities. What constitutes a clinically acceptable difference is ultimately a matter of judgment and may vary across patients, physicians, investigators, regulators, or payers.1 It is striking but perhaps not surprising that in trial registrations of noninferiority trials, the noninferiority margins are very often absent.2 A rational approach to planning noninferiority trials would involve performing a cost-utility analysis to derive the noninferiority margins before embarking on the trial. Such analyses could incorporate the different opinions of the various stakeholders.
Beerepoot M, ter Riet G, Geerlings SE. Lactobacilli vs Antibiotics to Prevent Recurrent Urinary Tract Infections: An Inconclusive, Not Inferior, Outcome—Reply. Arch Intern Med. 2012;172(21):1690–1694. doi:10.1001/2013.jamainternmed.111
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: